Robert H. Weiss, M.D.

Clinical/Research Interests

Robert H. Weiss' clinical interests include the diagnosis and treatment of all renal diseases and electrolyte problems. His research interests concern the cyclins and cyclin inhibitors, cancer growth control (kidney and breast cancer), metabolomics and proteomics, and polycystic kidney disease.

Title:

Professor, Chief of Nephrology, Sacramento VA Medical Center

Specialty:

Nephrology, Internal Medicine

Center/Program Affiliation:

UC Davis Comprehensive Cancer Center

Education:

UC Irvine College of Medicine
Irvine, California
M.D. 1984

UCLA
Los Angeles, California
M.S. 1980

UC Santa Cruz
Santa Cruz, California
B.A. 1976

Internships:

California-Pacific Medical Center
San Francisco, California
1984-1985

Residency:

California-Pacific Medical Center
San Francisco, California
1985-1987
Internal Medicine

Fellowships:

University of California, San Francisco
San Francisco, California
1991
Nephrology

Board Certifications:

American Board of Internal Medicine, Nephrology, 1996
American Board of Internal Medicine, 1987

Professional Memberships:

American Association for the Advancement of Science
American College of Physicians
American Society of Nephrology

Select Recent Publications:

Chen H, Li C, Huang j, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Kiu R, Weiss RH, Preyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M. CD4 T cells from elite controllers resist HIV-1 infection by selective upregulation of p21 cip-1/waf-1. Journal of Clinical Investigation. 2011 Apr 1;1214:1549-60.

Kim K, Taylor SL, Ganti S, Guo L, Osier M, Weiss RH. Urine metabolomic analysis identifies potential biomarkers adn pathogenic pathways in kidney cancer, Omics., 2011 May;155:293-303.

Tayor SL, Ganti S, Bukanov NO, Chapman A, Fiehn O, Osier M, Kim K, Weiss RH. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. American Journal of Physiology: Renal Physiology. 2010 298:909-922, with Editorial Forum

Liu , J.-Y. Park, S.-H., Morisseau , C., Hwang, S. H., Hammock, B., Weiss, RH., Sorafenib Has she Inhibitory Activity Which Contributes to Its Effect Profile in vivo, Molecular Cancer Therapeutics, 2009 Aug; 8(8):2193-203, 2009

Weiss, RH. Invited editorial (Weiss: Editor-in-Chief): Why another cancer journal? Cancers, 1(1):1-2, 2009

Perroud, B., Ishimaru, T., Borowsky, A.D., Weiss, RH. Grade-dependent proteomic characterization of kidney cancer, Molecular and Cellular Proteomics, May; 8(5):971-85, 2009

Kim, K.M., Aronov, P.A, Zakharkin, S.O., Anderson, D., Perroud, B., Weiss, RH., Urine metabolomic analysis for kidney cancer detection and biomarker discovery, Molecular and Cellular Proteomics, Mar; 8(3):558-70, 2009

Park SH, Wang X, Liu R, Lam KS, Weiss RH. High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers, Cancer Biology Therapy 2008 Dec 26;712.